<DOC>
	<DOCNO>NCT00428116</DOCNO>
	<brief_summary>Given high mortality associate infant HIV-1 fact surrogate marker poorly predictive mortality risk , empiric highly active antiretroviral therapy ( HAART ) initiation start infant young 12 month . A problem approach obligate infant life-long therapy , may associate cumulative drug toxicity , poor adherence , treatment failure . Early HAART prevention mortality first 2 year life potential salvage immune function alter viral set-point , allow withdrawal therapy , perhaps several year , subsequent CD4 % decline require . This untested approach attractive combine survival benefit early pediatric HAART therapy benefit antiretroviral deferral . One hundred fifty infant initiate HAART &lt; 13 month age treat HAART regimen 24 month immune reconstitution adequate growth ( ~100 ) randomize continued versus defer therapy . Clinical outcome , growth , toxicity compare child determine interruption safe beneficial strategy . Follow-up study closely monitor external Data Safety Monitoring Board ( DSMB ) .</brief_summary>
	<brief_title>Optimizing Pediatric HIV-1 Treatment , Nairobi , Kenya</brief_title>
	<detailed_description>Hypothesis : Deferring antiretroviral therapy infant immune reconstitution adequate growth follow early therapy primary infection ( initiated HAART primary infection le 13 month age ) compromise clinical status growth may spare antiretroviral toxicity . Specific Aim/Primary Objective : To compare growth morbidity infant ( initiated HAART primary infection less equal 13 month age subsequently normalize CD4 % growth follow 24 month HAART ) randomize deferred versus continuous therapy follow additional 18 month . Secondary Aim/Secondary Objective : To determine predictor non-progression HIV among infant , include : age , adherence , HIV-1 specific immune response , baseline HIV-1 RNA , CD4 percent immune activation . Design : Randomized clinical trial involve HIV-1 treatment infant ( &lt; 13 month old ) 24 month , follow randomization 18 month follow-up child randomize continued versus defer treatment . This trial unblinded . Population : HIV-1 infected infant ( &lt; 13 month ) newly initiate HAART HIV-1 infected infant already receive HAART initiate HAART age &lt; 13 month enrol . After 24 month treatment follow-up , child CD4 % &gt; 25 % normalized growth retain study randomize . Sample size : 150 infant enrol 100 expect eligible randomization ( 50 arm ) . Treatment : All infant treat HAART accord WHO Kenyan national guideline . The specific regimen use part study : First line regimen - AZT/3TC/NVP ( zidovudine/lamivudine/nevirapine ) - d4T/3TC/NVP ( stavudine/lamivudine/nevirapine ) - AZT/3TC/ABC ( zidovudine/lamivudine/abacavir ) - d4T/3TC/ABC ( stavudine/lamivudine/abacavir ) - ABC/3TC/NVP ( abacavir/lamivudine/nevirapine ) Second line regimen - ddI/ABC/LPV/r ( didanosine/abacavir/lopinavir-ritonavir ( Kaletra ) ) For infant prior exposure nevirapine part PMTCT : First line regimen - AZT/3TC/LPV/r ( zidovudine/lamivudine/lopinavir-ritonavir ( kaletra ) )</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>A . Infants newly initiate HAART Less 13 month age HIV1 DNA detection confirmation ( positive two HIV1 DNA filter paper test ) Caregiver infant plan reside Nairobi least 3 year ( report caregiver ) Caregiver able provide sufficient location information B . Infants already receive HAART Initiated HAART &lt; 13 month age Records confirm HIV positive status Documentation CD4 % weight prior HAART initiation Must 1st line drug regimen Eligibility randomization : Completed 24 month treatment HAART Normalized growth : weight height zscore ( WHZ ) &gt; 0.5 ; Child 's weight must 5th weightforage percentile weight curve must flat fall ( i.e . cross 2 major percentile line past 3 month ) CD4 % &gt; 25 Children recently initiate require antituberculosis treatment time randomization ineligible randomization .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>54 Months</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Pediatric</keyword>
	<keyword>HAART</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>